EYElmira R. Yerenchina

Elmira R. Yerenchina

*This is an algorithmically generated author record based on publicly available information.

Elmira R. Yerenchina has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of smoking and use of nicotine-containing products among medical students and physicians in CIS countries: a cross-sectional study

    by Oksana M. Drapkina, Oleg O. Salagay, Ruslan N. Shepel, Olga Yu. Kuznetsova, Ekaterina D. Savchenko, Elena A. Andreeva, Anna V. Turusheva, Marina A. Pokhaznikova, Gulbanu Z. Abdugulova, Akmaral B. Abdykulova, et al.

    BACKGROUND: To implement effective measures to reduce smoking and the use of novel nicotine-containing products among medical students and physicians, objective national-level data on smoking behavior are required. AIM: This work aimed to assess the prevalence of smoking and use of nicotine-containing products among medical students and primary care physicians in the CIS. METHODS: A cross-sectional consent-based survey was conducted. An online questionnaire administered via an electronic platform was used to assess the type of products consumed, frequency and duration of use, age of initiation, attempts to quit smoking, exposure to passive smoking, awareness of nicotine-related health risks, and availability of smoking cessation programs. RESULTS: The study included 9222 students and 1599 physicians from five countries. The prevalence of smoking among students and physicians, respectively, was: Russia 20.3% and 17.1%; Belarus 17.0% and 18.3%; Kyrgyzstan 15.4% and 6.8%; Kazakhstan 8.2% and 12.8%; Uzbekistan 3.2% and 5.9%. Smoking prevalence among women was lower than among men in all countries (p 0.05), except among students in Belarus (p 0.05). The prevalence of nicotine-containing product use (including combined use with conventional cigarettes) did not differ between men and women among students in most countries, except in Kyrgyzstan (p 0.05). The primary risk factors for smoking among students, regardless of country, were smoking by friends and smoking by classmates or dormitory roommates. Among physicians, 3.7%–12.5% of men and 10%–50% of women who reported quitting tobacco continued to use electronic cigarettes. Male physicians were more frequently exposed to passive smoking at work, whereas female physicians were more frequently exposed at home. Attitudes of healthcare professionals toward tobacco products and electronic cigarettes remarkably influenced the likelihood of using specific forms of smoking. CONCLUSION: This study expands current data on the prevalence of smoking, including passive smoking, as well as on cross-country similarities and differences in smoking behavior and smoking-related risk factors among healthcare professionals.


  • Open Access

    Changes in Mental and Physical Status and Potential Treatment for Patients with Post-COVID-19 Chronic Heart Failure

    by Zhannat M. Nurmakhanova, Zulfiya M. Zhankalova, Gulbanu Z. Abdugulova, Akmaral B. Abdykulova, Gulzhan H. Gabdulina, Aigul E. Tazhieva, Venera B. Khabizhanova, Indira S. Omarova, Zoya Zh. Ensegenova, Elmira R. Yerenchina, et al.

    BACKGROUND: Coronavirus infection can negatively impact the mental and physical status of patients with chronic heart failure, exacerbating anxiety and depressive symptoms. These changes should be recognized and addressed promptly. AIM: The study aimed to evaluate the impact of COVID-19 on the mental and physical status of patients with chronic heart failure who were eligible for treatment in primary care settings. METHODS: The study included patients with chronic heart failure of various origins with or without a history of COVID-19. The physical and mental health of all patients was evaluated using three scales: the Sheehan Patient-Rated Anxiety Scale, the Beck Depression Inventory, and the Social Adaptation Self-Evaluation Scale. Eligible patients with COVID-19 were prescribed sertraline, a selective serotonin reuptake inhibitor antidepressant, based on results of a psychometric evaluation. RESULTS: Sertraline is shown to significantly improve anxiety disorder, particularly severe cases, in patients with chronic heart failure who have recovered from COVID-19. Sertraline was found to be even more clinically effective in the treatment of depression; it improved depressive symptoms in all study groups. Sertraline was found to affect cardiovascular parameters in patients with chronic heart failure after COVID-19. Sertraline decreased heart rate, thereby improving the course of chronic heart failure. In addition, the ejection fraction remained virtually unchanged in the short term, which indicates the efficacy and safety of sertraline. This supports the recommendation to add sertraline to the combined therapy for this patient group. CONCLUSION: The study confirms the significant impact of COVID-19 on the physical and mental status of patients with chronic heart failure. However, the agents used to treat these conditions may affect the cardiovascular system. Patients require a comprehensive treatment strategy that includes support for mental and physical health.

  • Open Access

    Lung Function in Users of a Smoke-Free Electronic Device With HeatSticks (iQOS) Versus Smokers of Conventional Cigarettes: Protocol for a Longitudinal Cohort Observational Study

    by Almaz Sharman, Baurzhan Zhussupov, Dana Sharman, Irina Kim, Elmira Yerenchina

    Background: Chronic obstructive pulmonary disease (COPD) is a global public health problem. It is the third-leading cause of death in the world, the fourth leading cause of death in Kazakhstan, and is strongly associated with smoking. Smoking cessation reduces the severity of respiratory symptoms and COPD exacerbations. Heated tobacco products, such as HeatSticks heated by the iQOS device, a smoke-free electronic device, may serve as less risky alternatives to conventional combustible cigarettes. Objective: The purpose of this study is to evaluate frequency of exacerbations, respiratory symptoms, physical exercise intolerance, and abnormal lung functions, as well as other parameters and comorbidities among men and women aged 40-59 residing in Almaty, Kazakhstan, who use iQOS with HeatSticks compared to smokers of conventional cigarettes. Methods: This is a 5-year single-center cohort observational study. It includes two cohorts of participants consisting of men and women aged 40-59 residing in the city of Almaty, Kazakhstan: (1) smokers of combustible cigarettes (control group) and (2) users of iQOS with HeatSticks (exposure group). The study has baseline and periodic (ie, annual) comprehensive clinical assessments, as well as continuous COPD case-finding activities and registration of acute respiratory exacerbations over the course of the 5-year observation period. Study measures include spirometry, chest computed tomography, electrocardiography, physical exams, laboratory testing of serum for biomarkers of inflammation and metabolic syndrome, anthropometry, and the 6-minute walk test. Information about COPD symptoms will be collected using the COPD Assessment Test. Results: Participant recruitment began December 2017, and enrollment is expected to last until late summer 2018. Conclusions: This is the first cohort observational study in Kazakhstan to assess differences in lung function between users of the heated tobacco product, iQOS with HeatSticks, and smokers of conventional combustible cigarettes. The study results will add to knowledge on whether switching from combustible cigarettes to iQOS with HeatSticks affects respiratory symptoms and diseases, including the development and progression of COPD.


  • Open Access

    Lung Function in Users of a Smoke-Free Electronic Device With HeatSticks (iQOS) Versus Smokers of Conventional Cigarettes: Protocol for a Longitudinal Cohort Observational Study (Preprint)

    by Almaz Sharman, Baurzhan Zhussupov, Dana Sharman, Irina Kim, Elmira Yerenchina

    BACKGROUND Chronic obstructive pulmonary disease (COPD) is a global public health problem. It is the third-leading cause of death in the world, the fourth leading cause of death in Kazakhstan, and is strongly associated with smoking. Smoking cessation reduces the severity of respiratory symptoms and COPD exacerbations. Heated tobacco products, such as HeatSticks heated by the iQOS device, a smoke-free electronic device, may serve as less risky alternatives to conventional combustible cigarettes. OBJECTIVE The purpose of this study is to evaluate frequency of exacerbations, respiratory symptoms, physical exercise intolerance, and abnormal lung functions, as well as other parameters and comorbidities among men and women aged 40-59 residing in Almaty, Kazakhstan, who use iQOS with HeatSticks compared to smokers of conventional cigarettes. METHODS This is a 5-year single-center cohort observational study. It includes two cohorts of participants consisting of men and women aged 40-59 residing in the city of Almaty, Kazakhstan: (1) smokers of combustible cigarettes (control group) and (2) users of iQOS with HeatSticks (exposure group). The study has baseline and periodic (ie, annual) comprehensive clinical assessments, as well as continuous COPD case-finding activities and registration of acute respiratory exacerbations over the course of the 5-year observation period. Study measures include spirometry, chest computed tomography, electrocardiography, physical exams, laboratory testing of serum for biomarkers of inflammation and metabolic syndrome, anthropometry, and the 6-minute walk test. Information about COPD symptoms will be collected using the COPD Assessment Test. RESULTS Participant recruitment began December 2017, and enrollment is expected to last until late summer 2018. CONCLUSIONS This is the first cohort observational study in Kazakhstan to assess differences in lung function between users of the heated tobacco product, iQOS with HeatSticks, and smokers of conventional combustible cigarettes. The study results will add to knowledge on whether switching from combustible cigarettes to iQOS with HeatSticks affects respiratory symptoms and diseases, including the development and progression of COPD. CLINICALTRIAL ClinicalTrials.gov NCT03383601; https://clinicaltrials.gov/ct2/show/NCT03383601 (Archived by WebCite at http://www.webcitation.org/72BYoAKxa) INTERNATIONAL REGISTERED REPOR PRR1-10.2196/10006